Talquetamab-tgvs

(Talvey®)

Talvey®

Latest News

loading GIF

Drug updated on 4/16/2024

Dosage FormInjection (subcutaneous; 3 mg/1.5 mL (2 mg/mL) in a single-dose vial, 40 mg/mL in a single-dose vial)
Drug ClassBispecific GPRC5D-directed CD3 T-cell engagers
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Talquetamab-tgvs (Talvey) is approved for adults with relapsed or refractory multiple myeloma who have tried at least four previous treatments, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. This drug is a bispecific antibody that binds to the CD3 T-cell receptor and a tumor antigen on myeloma cells.
  • The data comes from a study that compared BCMA-targeting agents like Talvey to non-BCMA-targeting agents in treating this condition.
  • Efficacy varied across studies: the overall response rate ranged from 25% to 100%, complete response/stringent complete response rates from 7% to 38%, very good partial responses from 5% to 92%, and partial responses from about 5% to 14%. This variation suggests effectiveness could be influenced by patient subgroups or specific traits of the bispecific antibodies.
  • Non-BCMA targeting agents had potentially higher overall response rates, from 60% to 100%, indicating they might be effective alternatives for certain patient groups. Considerations such as previous treatment regimens, genetic variations, or other patient-specific factors could impact these outcomes.
  • Common adverse events associated with bispecific antibodies included cytokine release syndrome (17-82%), anemia (5-52%), neutropenia (12-75%), and thrombocytopenia (14-42%). Due to the wide range of prevalence, especially with cytokine release syndrome, careful monitoring is necessary during treatment.
  • Compared to traditional therapies such as proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies, Talvey shows promise, especially among heavily pretreated patients. The choice between BCMA-targeting drugs like Talvey and non-BCMA-targeting agents may depend on specific patient characteristics and previous treatment responses.

Product Monograph / Prescribing Information

Document TitleYearSource
Talvey (talquetamab-tgvs) Prescribing Information.2023Janssen Biotech, Inc., Horsham, PA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Multiple Myeloma, Version 2.2024, NCCN clinical practice guidelines in Oncology.2023Journal of the National Comprehensive Cancer Network